INSPHERO, INC

INSPHERO INC specializes in the development and manufacturing of advanced 3D human liver microtissues and associated functional assays for preclinical drug testing and toxicology research. The company leverages primary human hepatocytes, liver endothelial cells, and Kupffer cells to engineer physiologically relevant liver spheroids that replicate in vivo tissue architecture and metabolic function. Their technical expertise spans bioprinting, organoid culture systems, transcriptomics, and RNA-seq analysis to evaluate gene expression changes induced by siRNA/ASO therapeutics and environmental toxins. INSPHERO’s key differentiator lies in its ability to produce reproducible, human-derived liver models that outperform traditional 2D cell cultures and animal models in predicting clinical outcomes, enabling more accurate pharmacokinetic and hepatotoxicity assessments. The contractor maintains a consistent and deep relationship with the Department of Health and Human Services, delivering end-to-end biological research services focused on liver biology and therapeutic evaluation. Their work supports HHS missions in drug safety, precision medicine, and non-animal testing innovation, with recurring contracts for both manufacturing of biological constructs and analytical laboratory services. INSPHERO’s primary industry focus is in biological product manufacturing (NAICS 325414) and testing laboratories (NAICS 541380), positioning them at the intersection of regenerative biotechnology and translational pharmacology. They serve the preclinical research and biopharmaceutical development market by providing human-relevant, high-fidelity in vitro models that reduce reliance on animal testing and accelerate regulatory decision-making. As a small business structured as a 2L entity based in Brunswick, Maine, INSPHERO operates without federal certifications but maintains a focused geographic footprint in the Northeast biotech corridor. Their market positioning is defined by technical specialization in human-derived liver models rather than scale, making them a niche provider for agencies and researchers requiring physiologically accurate biological systems.